21st December 2020 Product update: rapidmicrobiology staff writer
New PCR Test to Differentiate Between COVID-19 and Flu
EUROIMMUN has announced the launch of the CE-marked EURORealTime SARS-CoV-2/Influenza A/B for direct detection of SARS-CoV-2, influenza virus type A and influenza virus type B.
It expands the testing portfolio for acute COVID-19 diagnostics by supporting differential diagnostics between SARS-CoV-2 infections and the common flu. It is available in countries accepting the CE mark.
PCR technology is considered the gold standard for direct pathogen detection. The new EURORealTime test allows fast detection and differentiation of genetic material from SARS-CoV-2, influenza virus type A and influenza virus type B using throat swab samples of patients with acute symptoms, which can be indicative for COVID-19 or flu.
Validation efforts revealed very high agreement of results obtained with the EURORealTime test and those obtained with reference PCR tests for SARS-CoV-2 and influenza A/B.
No cross-reaction with other common respiratory pathogens were detected. The assay is compatible with common real-time PCR thermal cyclers, while the EURORealTime Analysis Software allows for reliable and standardized evaluation of the test results.
Dr Wolfgang Schlumberger, CEO of EUROIMMUN commented on its launch: “As the flu season overlaps with the second wave of COVID-19, there is an increasing need to be able to quickly distinguish between SARS-CoV-2 and influenza infections. Individuals with these viral diseases can present with very similar symptoms which makes it difficult to differentiate between them."
"Direct pathogen detection plays a major role in the rapid and correct identification of these infections as it is essential for proper subsequent patient management,” “The combination of the three pathogens within this single multiparametric assay means saving valuable time and resources in the laboratories”, said Schlumberger.
The EURORealTime SARS-CoV-2/Influenza A/B assay adds to the company’s broad product portfolio of COVID-19 diagnostics. It is the second molecular assay for direct pathogen detection following the CE-marked and FDA-EUA approved EURORealTime SARS-CoV-2 assay.
The EURORealTime SARS-CoV-2/Influenza A/B assay adds to PerkinElmer’s PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel that previously received the CE- mark.
Date Published: 21st December 2020
Source article link: View
Note: This content has been edited by a rapidmicrobiology staff writer for style and content.